Acerta Pharma Bv

This early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check the safety and effectiveness of the drug pair. Part…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…

This early-phase study tested a combination of two drugs, acalabrutinib and obinutuzumab, in 69 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination was safe and could shrink or control the cancer. Participants included t…

This study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a high-risk genetic change (deletion 17p). The goal was to see how well the drug shrank tumors. Results showed that many patients had a p…